Teva Glipizide Extended-Release Tablets 5mg Recall: Failed Moisture Limits
Teva Pharmaceuticals USA recalls 5mg Glipizide Extended-Release Tablets due to failed moisture limits in stability testing. This may affect drug efficacy but does not pose immediate safety risks.
Lower-risk recall
Failed Moisture Limits: out of specification test results for water content obtained during stability testing.
Contact the company
What happened, in plain English
Teva Pharmaceuticals USA is recalling 5mg Glipiz:ide Extended-Release Tablets because moisture testing showed the product did not meet quality standards. This could mean the medication isn't as effective as it should be, but it does not pose an immediate safety risk to users. Read more at govinfonow.com/recall/41416-teva-glipizide-extended-release-tablets-5mg-recall-failed-moisture-limits.
Source Summary by GovInfoNow · govinfonow.com/recall/41416-teva-glipizide-extended-release-tablets-5mg-recall-failed-moisture-limits · Updated October 7, 2026 · FDA enforcement record: FDA #D-1058-2017
Cite this page
“Teva Glipizide Extended-Release Tablets 5mg Recall: Failed Moisture Limits.” GovInfoNow, updated October 7, 2026. https://govinfonow.com/recall/41416-teva-glipizide-extended-release-tablets-5mg-recall-failed-moisture-limits. Based on FDA recall #D-1058-2017 (https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-1058-2017%22&limit=1).
Why it’s dangerous
The tablets failed moisture testing during stability studies, meaning they may not be as effective as intended. However, this does not cause immediate harm like injury or illness. The issue is related to the medication's quality, not safety.
Who’s affected
People with diabetes who have been prescribed this medication and are using the recalled product. Those most at risk are individuals who rely on this medication for blood sugar control.
How to tell if you have this one
Check for the product name 'Glipizide Extended-Release Tablets', 5mg, 30 tablets per blister pack, with NDC code 0591-0844-15. The lot number 3138405A was manufactured for expiration 8/2017.
- Brand
Teva Pharmaceuticals USA- Category
Drug
What to do — step by step
Check Product Details
Look for the NDC code 0591-0844-15 and lot number 3138405A on the blister pack.
Where it went and when
Where it was distributed
Distributed in 6 states.
FDA distribution: “Product distributed to OH, IL, PA, MI, VA and CT” States read from FDA’s own wording; “not listed” means the notice does not name it.
States: Connecticut, Illinois, Michigan, Ohio, Pennsylvania, Virginia.
Recall timeline
FDA terminated this recall 7 months after the firm started it.
- Firm started the recall
- FDA classified it Class III
- Published in FDA’s Enforcement Report
- FDA terminated the recall
Dates from the agency record only; steps without a date are left out.
Similar recalls
Latest drug recalls
Keep exploring
Where this comes from
The facts (hazard, remedy, dates, manufacturer) are pulled from the official FDA recall record. The plain-language summary and step-by-step checklist are written by GovInfoNow to make the official notice easier to act on — they don’t replace it.
- Official source: FDA Recall #D-1058-2017 (August 2, 2017) — FDA publishes no per-recall page; this is the official machine-readable enforcement record. Search FDA recalls for D-1058-2017 to see it in context.
- Plain-language summary written by qwen3:4b on October 7, 2026, from the official record above. Not reviewed by a person — if it conflicts with the FDA notice, the notice is correct. Report an error on this page.
- GovInfoNow is an independent service and is not a government agency. We republish official FDA recall data; we don’t issue, amend or administer recalls.